US4459288A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic blood clotting factor compositions and their use
Assignee: Baxter International Inc
•
Filing: 1982-03-22
•
Granted: 1984-07-10
•
Expires: 2002-03-22
Abstract
Abstract Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; total factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10 are used in therapeutically effective amounts to treat blood clotting factor inhibitors.
Inventors
- 👤 William R. Thomas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 00:25
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/745; C07K14/755
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
47 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition comprising about from 20 to 112 units of F-IX/ml and from 0 to about 30 units of F-IX precursor/ml.
Claim 2
Independent Claim
47 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition comprising about from 20 to 112 units of F-IX/ml and from 0 to about 30 units of F-IX precursor/ml.
Claim 3
Independent Claim
46 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition comprising about from 1 to 50 units of F-X/ml and about from 4 to 10 units of F-Xa/ml.
Claim 4
Independent Claim
46 words
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition comprising about from 1 to 50 units of F-X/ml and about from 4 to 10 units of F-Xa/ml.
Claim 5
Independent Claim
24 words
The method of claims 1 or 2 wherein the therapeutically effective dose is greater than about 25 factor VIII correctional units/kg of patient weight.
Claim 6
Independent Claim
19 words
The method of claims 1 or 2 wherein the aqueous composition additionally comprises greater than 1.1 units of heparin/ml.
Claim 7
Independent Claim
15 words
The method of claims 1 or 2 wherein the aqueous composition additionally comprises antithrombin III.
Claim 8
Independent Claim
30 words
The method of claims 1 or 2 wherein the aqueous composition is sufficiently free of factor VIII antigen to not provoke an immune response in the patient to factor VIII.
Claim 9
Dependent Claim
59 words
A composition for the treatment of clotting factor deficiencies and inhibitors which comprises, in relative proportionate units, prothrombin, about from 1-10; thrombin, less than about 0.003, factor VII, about from 37-190; factor VIIa about from 8-80; factor IX, about from 15-112; factor IX precursor, 9 to about 30; factor X, about from 1-30; and factor Xa about from 1-10.
Claim 10
Dependent Claim
59 words
A composition for the treatment of clotting factor deficiencies and inhibitors which comprises, in relative proportionate units, prothrombin, about from 1-10; thrombin, less than about 0.003, factor VII, about from 37-190; factor VIIa about from 8-80; factor IX, about from 15-112; factor IX precursor, 9 to about 30; factor X, about from 1-30; and factor Xa about from 1-10.
Claim 11
Dependent Claim
57 words
A composition for the treatment of clotting factor inhibitors which comprises, in relative proportionate units, prothrombin, about from 3.6-8.9; thrombin, less than about 0.002, factor VII, about from 37-122; factor VIIa about from 25-78; factor IX, about from 20-81; factor IX precursor, 5 to about 20; factor X about from 1-25; and factor Xa about from 2-10.
Claim 12
Dependent Claim
57 words
A composition for the treatment of clotting factor inhibitors which comprises, in relative proportionate units, prothrombin, about from 3.6-8.9; thrombin, less than about 0.002, factor VII, about from 37-122; factor VIIa about from 25-78; factor IX, about from 20-81; factor IX precursor, 5 to about 20; factor X about from 1-25; and factor Xa about from 2-10.
Claim 13
Dependent Claim
57 words
A composition for the treatment of clotting factor inhibitors which comprises, in relative proportionate units, prothrombin, about from 3.6-5.9; thrombin, less than about 0.001, factor VII, about from 39-88; factor VIIa about from 25-60; factor IX, about from 50-80; factor IX precursor, 5 to about 12; factor X about from 1-13; and factor Xa about from 4-10.
Claim 14
Dependent Claim
57 words
A composition for the treatment of clotting factor inhibitors which comprises, in relative proportionate units, prothrombin, about from 3.6-5.9; thrombin, less than about 0.001, factor VII, about from 39-88; factor VIIa about from 25-60; factor IX, about from 50-80; factor IX precursor, 5 to about 12; factor X about from 1-13; and factor Xa about from 4-10.
Claim 15
Dependent Claim
28 words
A composition for treating clotting factor inhibitors which comprises about from 20-112 proportionate units of factor IX and above 0 to about 30 units of factor IX precursor.
Claim 16
Dependent Claim
28 words
A composition for treating clotting factor inhibitors which comprises about from 20-112 proportionate units of factor IX and above 0 to about 30 units of factor IX precursor.
Claim 17
Dependent Claim
27 words
An aqueous composition for treating clotting factor inhibitors which comprises about from 1 to 13 units of F-X/ml and about from 4 to 10 units of F-Xa/ml.
Claim 18
Dependent Claim
27 words
An aqueous composition for treating clotting factor inhibitors which comprises about from 1 to 13 units of F-X/ml and about from 4 to 10 units of F-Xa/ml.
Claim 19
Dependent Claim
18 words
The compositions of claims 6, 7, 8 or 9 additionally comprising greater than 1.1 proportionate units of heparin.
Claim 20
Dependent Claim
9 words
The composition of claim 12 additionally comprising antithrombin III.
Claim 21
Dependent Claim
28 words
The composition of claims 7, 8, 9 or 10 which is sufficiently free of factor VIII antigen to not provoke an immune response to factor VIII in humans.
Claim 22
Dependent Claim
12 words
The composition of claims 7, 8 or 9 dissolved in aqueous solution.
Claim 23
Dependent Claim
32 words
The composition of claim 10 dissolved in an aqueous solution to a concentration of about from 20-112 units of factor IX/ml and about 0 to about 30 units of factor IX precursor/ml.
Claim 24
Dependent Claim
17 words
The composition of claim 10 further including about from 8 to 80 proportionate units of factor VIIa.
Claim 25
Dependent Claim
16 words
The composition of claim 10 containing about from 25 to 78 proportionate units of factor VIIa.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-10 | 1988-01-09 | 1988-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-10 | 1992-01-09 | 1992-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-10 | 1996-01-09 | 1996-07-10 | $7700.00 | Window Closed / Lapsed |